Portfolio company
Meacor
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Meacor develops a catheter-based medical device for repairing heart valves to treat patients with mitral and tricuspid regurgitation without undergoing open-heart surgery.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
CardioMech
CardioMech develops a transcatheter-based artificial chordae delivery system for hospitals to treat patients suffering from degenerative mitral regurgitation without open-heart surgery.
CoreMedic
This company develops transcatheter heart valve repair systems to treat mitral valve regurgitation for patients requiring minimally invasive cardiac interventions.
Nyra Medical
The company develops a transcatheter cardiac implant to treat mitral regurgitation for patients requiring minimally invasive heart valve repair.
Valcare Medical
The company develops transcatheter repair and replacement technologies for heart valves to treat patients with mitral and tricuspid regurgitation.
CardioMech AS
This company develops catheter-based artificial chords to repair mitral valves for patients suffering from degenerative mitral regurgitation.
HVR Cardio
This company develops transcatheter mitral valve repair devices to treat patients with mitral regurgitation.
TRiCares
This company develops a catheter-based tricuspid valve replacement system for patients suffering from tricuspid regurgitation.
TRICUSPID VALVE REPAIR
Versa Vascular develops a transcatheter tricuspid valve repair system for patients suffering from tricuspid regurgitation to restore heart function without requiring open-heart surgery.